Objective: This clinical trial aims to evaluate if natural mixed carotenoids supplementation can improve the health and survival of acquired immunodeficiency syndrome (AIDS) patients. Design: A placebo-controlled, prospective, randomized, double-blind, multicenter clinical trial. Setting: Community, tertiary care human immunodeficiency virus (HIV) clinics of the Canadian HIV Trials Network (CTN). Participants: Three hundred and thirty-one adults with advanced AIDS on conventional management were recruited during routine clinic visits. Interventions: All participants, including 166 controls, received daily oral specially formulated multivitamins including vitamin A and trace elements; 165 treatment group participants received additional daily oral natural mixed carotenoids, equivalent to 120 000 IU (72 mg) of b-carotene daily. Follow-up was quarterly at routine clinic visits. Results: Mean (s.d.) follow-up was for 13 (6) months. Thirty-six participants died by 18 months. Serum carotene concentration o1.0 mmol/l was present in 16% participants at baseline. Despite variation in carotene content of the treatment medication, serum carotene concentrations increased significantly to twice the baseline levels to 18 months follow-up in participants who received carotenoids treatment compared with controls (Po0.0001). Although not statistically significant, mortality was increased in participants who did not receive carotenoids treatment compared with those who did (HR time to death 1.76, 95% CI 0.89, 3.47, P ¼ 0.11). In multivariate analysis, survival was significantly and independently improved in those with higher baseline serum carotene concentrations (P ¼ 0.04) or higher baseline CD4 T-lymphocyte counts (P ¼ 0.005). Adjusted mortality was also significantly and independently increased in those who did not receive carotenoids treatment compared with those who did (HR time to death 3.15, 95% CI 1.10, 8.98, P ¼ 0.03).
Introduction
Individuals in all stages of human immunodeficiency virus (HIV) infection commonly have low circulating concentrations of micronutrients including vitamin A and carotenoids (Bogden et al., 1990; Beach et al., 1992; Coodley et al., 1993a; Sappey et al., 1994; Ullrich et al., 1994; Lacey et al., 1996; Omene et al., 1996; Skurnick et al., 1996) , even in developed countries where dietary micronutrient intake is high (Baum et al., 1994) . In observational studies, low micronutrient concentrations, including vitamin A and carotenoids, are associated with HIV disease progression, mortality and vertical viral transmission (Semba et al., 1993; Baum et al., 1995; Stephensen, 2003) , and higher intake with delayed disease progression and survival (Tang et al., 1993; Tang et al., 1996) . Vitamin A supplementation of children reduces morbidity and mortality of childhood infectious disease, specially with deficiency (Villamor and Fawzi, 2000) , and supplementation of HIV-infected pregnant women improves some outcomes in the children (Kumwenda et al., 2002) . Multivitamin supplementation of adults with HIV, but not vitamin A, has beneficial effects on HIV-related outcomes (Jiamton et al., 2003; Stephensen, 2003; Fawzi et al., 2004) .
Some carotenoids are dietary sources of vitamin A. Carotenoids also have antioxidant, immune-enhancing and anticancer action in vitro (Bendich, 1993) . Supplementation with b-carotene, the principal carotenoid, increases immune activity in healthy adults (Alexander et al., 1985) , may reduce risk of adenoma recurrence when combined with vitamin A (Steck-Scott et al., 2004) , but with other micronutrients has no benefit on cancer and cardiovascular disease (The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group, 1994; Hennekens et al., 1996; Omenn et al., 1996) , except combined b-carotene, vitamin E and selenium in an undernourished population (Blot et al., 1993) .
Low serum carotene concentration is associated with increased HIV seroconversion in patients with sexually transmitted diseases (Mehendale et al., 2001) . In small studies, b-carotene supplementation of HIV-seropositive individuals has no conclusive effect on viral load and immune cell subsets (Garewal et al., 1992; Coodley et al., 1993b Coodley et al., , 1996 Silverman et al., 1994; Fryburg et al., 1995; Nimmagadda et al., 1998) . b-Carotene supplementation alleviates acquired immunodeficiency syndrome (AIDS)-related and erythropoietic protoporphyria-related symptoms (Bianchi-Santamaria et al., 1992; Mathews-Roth, 2000) , and may reduce pregnancy-related mortality in combination with vitamin A (West et al., 1999) . Vitamin A is toxic at high doses and upregulates HIV-1 expression in monocytes in vitro (Turpin et al., 1992) , whereas conversion of carotenoids to vitamin A is auto-regulated. No recommended daily allowance or tolerable upper intake level has been set for carotenoids (Institute of Medicine, 2000) , and they are safe with long-term use (Mathews-Roth, 1986) . Anecdotal adverse effects of b-carotene supplementation (Mathews-Roth, 1986), a possible adverse effect in smokers and in those with asbestos exposure (The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group, 1994; Hennekens et al., 1996; Omenn et al., 1996) , and the association of HIV disease acceleration and death with high b-carotene intake in an observational study (Tang et al., 1993 (Tang et al., , 1996 remain to be confirmed in randomized clinical trials.
Micronutrient dosage adequate for the general population is considered inadequate for HIV-infected persons (Baum et al., 1994; Skurnick et al., 1996) . As unprescribed multivitamins are widely used by HIV-infected persons (Skurnick et al., 1996) , a placebo-controlled study of micronutrient supplementation is impractical in developed countries, and may be unethical (Coodley et al., 1996) . We administered a specially formulated preparation of multivitamins and trace elements including vitamin A to both study groups in this community-based, randomized, double-blind, controlled clinical trial aimed at testing if supplementation with oral natural mixed carotenoids and micronutrients can improve the health or survival of AIDS patients on conventional management including antiretroviral therapy (ART).
Materials and methods

Participants
Eligible participants who consented were recruited from 22 centers of the Canadian HIV Trials Network (CTN) across Canada between August 1997 and May 1999. Participants were HIV-seropositive, at least 18 years old and at risk for progression of HIV immune disease. Risk of disease progression was defined according to anti-HIV treatment status, CD4 T-lymphocyte counts and plasma HIV-1 viremia levels as follows: CD4 T-lymphocyte count below 50 cells/ml, and expected stability of ART; CD4 T-lymphocyte count nadir below 50 cells/ml, and stabilized under 150 cells/ml with protease inhibitor-based combination ART for at least 3 months; or CD4 T-lymphocyte count stabilized below 200 cells/ml, and plasma viremia greater than 20 000 copies/ ml (RT-PCR) or 10 000 copies/ml (bDNA), and on stable protease inhibitor-based combination ART for at least 3 months. Patients were excluded if they had shown continuing CD4 T-lymphocyte improvement on combination protease inhibitor-based anti-HIV therapy, had severe preexisting hepatic dysfunction, had missed two earlier clinic appointments without prior arrangement or had acute opportunistic infection.
Study design and intervention
The study was a randomized, double-blind, placebo-controlled multicenter clinical trial. Eligible participants were randomized into two groups: carotenoids treatment and control. Participants in both groups received daily oral specially formulated multivitamins including vitamin A and trace elements. Participants in the carotenoids treatment group received additional natural mixed carotenoids, equivalent to 120 000 IU (72 mg) b-carotene daily, whereas participants in the control group did not. The carotenoids and multivitamins were co-formulated into one caplet (USANA Health Sciences Inc., Salt Lake City, UT, USA) (see Appendix B). Both carotenoids treatment and control preparations were identical in appearance, and were taken as two caplets twice a day or four caplets once a day. Participants continued other prescribed therapy, were offered Pneumocystis carinii pneumonia (PCP) prophylaxis, could be in other clinical trials and could take other multivitamin supplements not containing carotenoids or vitamin A. At the start of the study, the daily dose of the study medication was measured by assays to be 88% of the formulated dose, or the equivalent of 106 880 IU (64 mg) of b-carotene, and had reduced to 13% or 15 000 IU (9.2 mg) of b-carotene during the course of the study. This residual dose is still several times larger than the estimated daily adult carotenoids intake (Institute of Medicine, 2000) .
Study procedures
Consenting participants were enrolled into the study by the investigators or staff during routine clinic visits. The following procedures were carried out at screening or baseline visit: a complete medical history, including previously diagnosed medical conditions, opportunistic infections and medications; a complete physical examination; CD4 and CD8 T-lymphocyte counts and plasma HIV-1 viral load; and biochemical evaluation including serum carotene levels. The term serum carotene refers to serum b-carotene. We did not measure levels of other carotenoids.
Using a computerized program, allocation to study group was stratified by center using permuted blocks of four from randomization lists prepared before the study by personnel at the data center of the CTN. The site coordinator telephoned a central coordinator at the data center for the next allocation of a consenting eligible participant and this was relayed to the site pharmacy. Trial participants and clinicians were blinded to study group allocation.
Participants were re-evaluated during quarterly routine physician visits by clinical examination and laboratory tests similar to those at baseline. All new AIDS-defining events and adverse events and their relationship to the study medication were blindly adjudicated (PP). Study medication was dispensed quarterly, and self-reported adherence to treatment was documented. Results of blood tests were valid within 30 days of the quarterly schedule.
Outcome measures
Clinical outcome measures were time to new or recurrent AIDS-defining illness or death, or time to death from any cause. A new AIDS-defining illness was as described (Centers for Disease Control, 1992) , except that to be considered a recurrence, an episode of PCP must have occurred at least 6 months after the preceding one. Laboratory outcome measures included changes from baseline in CD4 T-lymphocyte count and plasma HIV-1 viremia.
Sample size
It was estimated that 200 events would have to be observed to detect a 33% reduction in hazard time to new or recurrent AIDS-defining illness or death, at a power of 80%, a twotailed a of 0.05 and an estimated hazard rate of 0.019. This was expected to require 225 patients in each group, and continued follow-up for 26 months beyond recruitment of the last patient. Accrual was expected to require 12 months. The study closed prematurely, however, owing to interruption in supply of the study medication, with the recruitment of 331 patients and median (s.d.) follow-up of 13 (6) months.
Statistical analysis
Analysis was by intention to treat, and included all participants randomized to study medication. All analyses were performed using SAS and S-plus software. At the onset of the study, an interim analysis using the O'Brien Fleming approach was planned with the occurrence of 100 events, to be tested with an a value of 0.005 (O'Brien and Fleming, 1979 ). An a value of 0.048 was reserved for the final analysis, to give an overall error of 0.05 for the whole study.
The Wilcoxon rank-sum test was used to compare the effect of carotenoids treatment at follow-up on CD4 Tlymphocyte count, serum carotene concentration and plasma viral load. Time to development of new or recurrent AIDS-defining illness or death, time to death and adverse events defined as non-AIDS hospitalization were compared between treatment and control groups using the log-rank test. Analyses adjusted for clinically important prognostic risk factors were carried out using the Cox proportional hazards model. Both unadjusted hazard rates and adjusted hazard rates are presented.
Protocol approval
Approval was obtained from Health Canada for use of carotenoids as an investigational new drug. The study protocol was reviewed and approved by the Scientific Review Committee and the National Ethics Review Committee of the CTN, and the Institutional Review Board of each participating center. All participants gave written informed consent.
Results
Beginning in August 1997, 331 eligible and consenting participants were randomized to carotenoids treatment and control groups, and included in the intention-to-treat analysis (Figure 1 ). The study closed early at a mean (s.d.) duration of follow-up of 13 (6) months. The demographic and clinical characteristics of participants in the two study groups were similar (Table 1) . Two hundred and seventyeight (84%) participants were tested for serum carotene concentration owing to limited access at two centers; 44/278 (16%) had values below 1.0 mmol/l (population-based reference range for The Ottawa Hospital: 1.0-5.5 mmol/l), and the median was 1.8 mmol/l (Table 1) .
At 6 months, median serum carotene concentration increased to approximately twice the baseline level with carotenoids treatment, whereas there was no change in controls (Po0.0001), and a statistically significant difference compared with controls was maintained until 18 months (Figure 2a ). At 12, 15 and 18 months follow-up, median CD4 T-lymphocyte counts also showed statistically significant improvement (Figure 2b ), but there was no change in viral load (Figure 2c) .
Thirty-six deaths occurred, 13/165 (7.9%) in the carotenoids treatment group and 23/166 (13.9%) in controls, and new or recurrent AIDS-defining event or death occurred in 25/165 (15.2%) versus 36/166 (21.7%) (Table 2a) . Although the primary outcome of time to new or recurrent AIDS or death showed no difference in controls versus carotenoids treatment group (P ¼ 0.18), intention-to-treat time to death (P ¼ 0.11) and on-treatment time to death (P ¼ 0.06) (Table 2a and Figure 3) showed a trend towards increased mortality. There was no significant difference between controls and carotenoids treatment group either in the number of participants experiencing new or recurrent episodes of AIDS-defining illness (13.3 versus 10.9%, HR 1.21, 95% CI 0.65, 2.25, P ¼ 0.56) or in the number of participants hospitalized for reasons not related to AIDSdefining illness (13.3 versus 12.7%, HR 1.00, 95% CI 0.55, 1.82, P ¼ 0.99).
In univariate analysis, higher baseline CD4 T-lymphocyte counts (HR 0.60 Mixed carotenoids in HIV infection J Austin et al increase) and higher baseline serum carotene concentrations (HR 0.61, 95% CI 0.39, 0.94, P ¼ 0.03, per 1 mmol/l increase) were both significantly associated with reduced mortality, but baseline viral load had no significant effect on death (HR 0.58, 95% CI 0.29, 1.18, P ¼ 0.13, below versus above median). In a stratified analysis, with baseline CD4 cell counts above 50 cells/ml, there were 9.5% deaths in controls and none in participants in the carotenoids treatment group (P ¼ 0.004), whereas the proportionate difference in deaths between study groups was smaller and not statistically significant with CD4 cell counts below 50 cells/ml (P ¼ 0.56) ( Table 3) . With baseline serum carotene concentrations below the median of 1.8 mmol/l, there were threefold more deaths in controls than in carotenoids treatment group (P ¼ 0.03), whereas the proportionate difference in deaths between study groups was smaller and not statistically significant with serum carotene concentrations above the median (P ¼ 0.68) ( Table 3 ). The suggested interaction between baseline carotene concentrations and effect of carotenoids treatment on mortality was not statistically significant, but the power to detect an interaction was low.
In covariate analyses, adjusting for carotenoids treatment, regression analysis of intention-to-treat time to death and each baseline predictor showed a significantly reduced risk of death for participants with higher baseline serum carotene concentrations (HR 0.25, 95% CI 0.10, 0.63, P ¼ 0.004, square root of serum carotene) and higher baseline CD4 Tlymphocyte counts (HR 0.60, 95% CI 0.46, 0.78, P ¼ 0.0002, per 25 cells increase), whereas plasma HIV-1 load had no effect on death (HR 1.76, 95% CI 0.87, 3.54, P ¼ 0.11, above versus below median).
Multivariate analysis showed that controls had an independent and statistically significant increased risk of death than those on carotenoids treatment (HR 3.15, 95% CI 1.10, 8.98, P ¼ 0.03) ( Table 2) . Also in multivariate analysis, participants with higher baseline serum carotene had an independent and statistically significant reduced risk of death (HR 0.59, 95% CI 0.35, 0.99, P ¼ 0.04, per 1 mmol/l increase); so did those with higher baseline CD4 T-lymphocyte counts (HR 0.63, 95% CI 0.46, 0.87, P ¼ 0.005, per 25 cells increase) ( Table 2b ). The effect of baseline ART, or of other predictors, on death or on new or recurrent AIDSdefining event, was negligible.
Discussion
In the current study, we observed that low serum carotene concentrations were common at baseline. Participants with lower baseline serum carotene, and, as expected, those with lower baseline CD4 T-lymphocyte counts were independently at significantly increased risk of death. Monitoring of formulated carotene stability during the study revealed a decline in drug activity in the formulation, which is commonly seen in commercially available formulations (Foster et al., 2002) . Despite lack of uniformity in the dose of the study medication and early termination of the trial, we observed a significant elevation in serum carotene to 18 months follow-up. We did not observe a significant effect of Follow-up of baseline characteristics with carotenoids treatment versus controls: (a) serial median serum carotene concentration showed a statistically significant increase from baseline with carotenoids treatment at 3 (Po0.0001), 6 (Po0.0001), 9 (Po0.0001), 12 (Po0.0007) and 18 (Po0.001) months; (b) serial median change from baseline in CD4 T-lymphocyte count showed a statistically significant increase with carotenoids treatment at 12 (P ¼ 0.04), 15 (P ¼ 0.007) and 18 (P ¼ 0.008) months; and (c) serial median percent change from baseline in log 10 plasma viral load showed no change with carotenoids treatment. Comparisons between the study groups were made using the Wilcoxon rank-sum test. Error bars denote inter-quartile range (IQR).
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carotenoids treatment on the primary outcome of new or recurrent AIDS-defining event or death. Nevertheless, a reduction in the secondary outcome of overall mortality was apparent on adjusting for known and demonstrated covariates CD4 T-cell count and serum carotene concentration. Also, the beneficial effect of carotenoids treatment on overall survival was greater in participants with lower baseline concentrations of serum carotene or higher baseline CD4 T cell counts. This internal and external consistency of findings supports the apparent treatment effect of carotenoids. The interpretation of this apparent treatment effect is further supported by the baseline similarity of randomized groups, masking and the concrete outcome of survival. HIV-seropositive persons have reduced serum concentrations of vitamin A, carotene and individual carotenoids in all stages of HIV infection (Sappey et al., 1994; Ullrich et al., 1994; Phuapradit et al., 1996) , and reduction of serum carotene concentration is greater than other antioxidants (Sappey et al., 1994) . Allard et al. (1998) report mean serum carotene concentrations in HIV-seropositive and -seronegative individuals as 0.23 and 0.38 mmol/l, respectively, and Ullrich et al. (1994) as 0.47 and 1.37 mmol/l, respectively. Low serum carotene concentrations occur in 30-77% of HIVseropositive adults (Bogden et al., 1990; Ullrich et al., 1994) , although studies use different and arbitrary definitions of a low carotene concentration. Serum carotene concentrations are affected by severity of HIV immune disease, gender mix of the population, recent intake and laboratory testing conditions. Besides low dietary intake, low serum carotene concentrations in HIV-infected persons may be because of malabsorption, diarrhea, altered gut barrier function, altered metabolism (Keating et al., 1995) and oxidative stress (Sappey et al., 1994; Allard et al., 1998) . The extent of reduction of serum carotene is secondary to its oxidation and consequent depletion by singlet oxygen (Bendich, 1993) . Circulating concentrations of drugs can also be lower in the HIV-infected than in the HIV-uninfected (Sahai et al., 1997) . We chose treatment with a relatively high dose of natural mixed carotenoids in the current trial because of the known absorption defect in AIDS that affects drug and micronutrient concentrations, and because similar doses of carotenoids are safe in short-and long-term use.
In our cohort of advanced HIV disease, we observed a twofold, statistically significant increase in serum carotene concentrations. On supplementation with 180 mg of oral bcarotene daily, serum carotene concentrations increase 4.5-fold at 4 weeks in adults with HIV infection (Coodley et al., 1993b) and 13-fold at 2 weeks in healthy adults (Alexander et al., 1985) . There was no association between baseline serum carotene concentrations and baseline CD4 T-lymphocyte counts (results not shown), as others have reported (Sappey et al., 1994; Ullrich et al., 1994; Phuapradit et al., 1996) .
The magnitude of the apparent carotenoids treatment effect on mortality in the current study was large, and approached that of ART in AIDS patients (Hammer et al., 1997; Cameron et al., 1998) . This treatment effect was not, however, reflected in antiviral activity, tempo of the CD4 Tlymphocyte response or occurrence of AIDS-defining illnesses. The prediction of mortality by lower baseline serum carotene concentration and the apparent greater effect of carotenoids treatment with lower baseline serum carotene concentration suggest that treatment may be addressing a deficiency. In a pilot single-blind uncontrolled trial, supplementation with 60 mg b-carotene daily was associated with alleviation of several symptoms of AIDS-related complex (Bianchi-Santamaria et al., 1992) . In our study, as both groups received multivitamins including vitamin A in a wellcontrolled prospective double-blind study design, therapeutic action may be specific to carotenoids, and supplementary to any therapeutic benefit of multivitamin and mineral supplementation in both groups. In a cross-over placebo-controlled study of b-carotene supplementation at 180 mg daily, a significant increase in CD4 cells (Coodley et al., 1993b) was not duplicated when both groups also received multivitamins, which the authors attribute to possible beneficial effect of multivitamins in both groups (Coodley et al., 1996) . In a randomized placebocontrolled underpowered clinical trial in 481 ART-untreated adults with HIV infection, supplementation with micronutrients showed a salutary effect on survival with no accompanying changes in immune cells (Jiamton et al., 2003) . In a large randomized placebo-controlled multifactorial clinical trial in ART-untreated women with HIV infection, supplementation with vitamins B, C and E had a beneficial effect on outcomes related to disease progression, whereas combined vitamin A and b-carotene did not (Fawzi et al., 2004) .
The mechanism of action of the apparent treatment effect of carotenoids in the current study is not known. It may be through the conversion of carotenoids to vitamin A in the face of deficiency, the independent antioxidant action of carotenoids that are absorbed unchanged or the altering of the pharmacokinetics of protease inhibitor anti-HIV drugs. Supplementation with b-carotene decreases the concentration of biological markers related to oxidative stress in HIV-seropositive persons (Delmas-Beauvieux et al., 1996; Constans et al., 1998) . Interaction occurs between micronutrients and antiretroviral drugs (Toma et al., 2001; Foster et al., 2002) , possibly affecting serum concentrations of antiretrovirals or micronutrients. Micronutrient interactions may also be associated with reduced morbidity of infections (Rahman et al., 2001) and improved response to drugs (Karyadi et al., 2002) .
The independent prediction of mortality by low baseline CD4 T-lymphocyte counts that we observed is well recognized (Hammer et al., 1997; Cameron et al., 1998) . The significantly greater carotenoids treatment effect in participants with higher baseline CD4 T-lymphocyte counts, however, occurred after the onset and peak of increase in serum carotene concentrations, and after a large proportion of deaths in both study groups. Also, changes in plasma viremia and AIDS-defining illness did not accompany reduction in mortality, and outcomes and baseline ART status were not associated in multivariate analysis. Baseline or subsequent ART profile is, therefore, unlikely to be an explanation for the apparent carotenoids treatment effect. The slightly fewer participants on protease inhibitor-based combination ART and slightly greater number not on HIV drug treatment in the treatment group compared with controls could only have reduced the magnitude of apparent carotenoids treatment effect.
The findings of the current study are consistent with other studies. They show internal consistency in the association of higher baseline CD4 T-lymphocyte count and survival, of lower baseline serum carotene concentration and mortality, and of micronutrient supplementation and greater clinical response in the presence of deficiency. Our findings can be generalized to adults with advanced AIDS with probable dietary adequacy, concomitant albeit inadequate ART and with the specific accompanying multivitamin supplement. Although desirable, it may not be ethical to limit enrollment in future studies to patients with low serum carotene concentrations.
A positive effect of carotenoids supplementation was seen on survival of immunocompromised AIDS patients in this controlled trial, even with the unplanned uneven carotene content of the medication. This underscores the importance of further research into the role of micronutrients in AIDS management. A larger study must corroborate the findings and investigate the relationship of therapeutic effect to dose of carotenoids, pre-existing carotene and vitamin A deficiencies, presenting illness and concomitant ART. The stability of the carotene supplements must be monitored during studies, as nutritional supplements are not regulated by quality standards. Today, when ART is expected to be successful in most cases, natural mixed carotenoids supplementation may be a potential low-cost intervention for those with inadequate response to conventional treatment or lacking access to ART. 
